# Use of Ozone-Depleting Substances; Removal of Essential-Use Designation (Flunisolide, etc.); Correction
> **Food and Drug Administration** · Final rule; correction. · Published 2010-09-17 · 75 FR 56858
## Document
- **Document number:** 2010-23195
- **Category:** other
- **Sub-agency:** Food and Drug Administration
- **Federal Register citation:** 75 FR 56858
- **CFR reference:** 21 CFR 2
- **Publication date:** 2010-09-17
- **HHS docket:** Docket No. FDA-2006-N-0304
## Abstract

The Food and Drug Administration (FDA) is correcting a final rule that appeared in the Federal Register of April 14, 2010 (75 FR 19213). The document amended FDA's regulation on the use of ozone- depleting substances (ODSs) in self-pressurized containers to remove the essential-use designations for flunisolide, triamcinolone, metaproterenol, pirbuterol, albuterol and ipratropium in combination, cromolyn, and nedocromil used in oral pressurized metered-dose inhalers (MDIs). The document was published with an inadvertent error. This document corrects that error.

## Source
- [Federal Register document](https://www.federalregister.gov/documents/2010/09/17/2010-23195/use-of-ozone-depleting-substances-removal-of-essential-use-designation-flunisolide-etc-correction)
---
*AI Analytics · CC0 1.0*